The effect of vitamin D administration on the clinical and laboratory symptoms of adolescents suffering from polycystic ovary syndrome with vitamin D deficiency

Document Type : Original Article

Authors

1 Gynecologist and obstetrician, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.

2 Professor, Department of Statistics, Social Factors Affecting Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.

3 Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.

10.22038/ijogi.2024.70923.5626

Abstract

Introduction: Since conflicting results have been reported about the relationship between the level of vitamin D in people with polycystic ovary syndrome and related metabolic disorders, the present study was performed with aim to determine the effect of vitamin D administration on the clinical and laboratory symptoms of adolescents with polycystic ovary syndrome with vitamin D deficiency.
Methods: This double-blind randomized controlled clinical trial study was performed on 50 patients with sonographic evidence of polycystic ovary syndrome with vitamin D deficiency in two control and intervention groups. The intervention group was given vitamin D and the control group was given placebo. Clinical, laboratory and sonographic symptoms before and after the intervention were compared in two groups. Data were analyzed by SPSS software (version 16), Man-Whitney U and Wilcoxon test. P<0.05 was considered statistically significant.
Results: The intervention improved the level of vitamin D in the case group (P<0.001). There was significant difference between the case and control groups in terms of fasting insulin level (P=0.001), serum testosterone level (P<0.001), free testosterone level (P=0.042), LH to FSH ratio (P<0.001), LH level (P<0.001), diastolic blood pressure (P=0.027), and severity of hirsutism (P=0.016). Polycystic ovary syndrome and Oligomenorrhea was more in the control group (P <0.01); However, there was no significant difference between the two groups in terms of fasting blood sugar, triglycerides, HDL, systolic blood pressure, acne severity, and ovarian volume (P>0.05).
Conclusion: Considering the role of vitamin D in ovum development and its relationship with the reduction and regulation of insulin, the use of this supplement is recommended to improve the clinical and laboratory symptoms of polycystic ovary syndrome and subsequently correct menstrual disorders and hyperandrogenism. Also, in this study, vitamin D consumption did not cause a significant difference in insulin resistance between the two groups after the intervention.

Keywords

Main Subjects

References

  1. Rasekhjahromi A, Kargarfard Sh, Kargarfard F, Kalani N. Clomiphene citrate Versus Cabergoline in Ovulation Induction by letrozole: A randomized clinical trial Study on of Infertile Polycystic Ovary Syndrome Women. Journal of Medicinal and Chemical Sciences 2022; 5(4):587-95.
  2. Kumarapeli V, Seneviratne RD, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semiurban population in Sri Lanka. American journal of epidemiology 2008; 168(3):321-8.
  3. Arslanian SA, Witchel SF. Polycystic ovary syndrome in adolescents: is there an epidemic?. Current Opinion in Endocrinology, Diabetes and Obesity 2002; 9(1):32-42.
  4. Chang RJ, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. Clinical obstetrics and gynecology 2007; 50(1):178-87.
  5. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Australian and New Zealand Journal of Obstetrics and Gynaecology 1994; 34(1):67-72.
  6. Driscoll DA. Polycystic ovary syndrome in adolescence. InSeminars in reproductive medicine 2003; 21(3):301-8.
  7. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. The journal of clinical endocrinology & metabolism 1999; 84(11):4006-11.
  8. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine reviews 2012; 33(6):981-1030.
  9. Brzozowska M, Karowicz-Bilińska A. The role of vitamin D deficiency in the etiology of polycystic ovary syndrome disorders. Ginekologia Polska 2013; 84(6).
  10. Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, et al. Low levels of 25 (OH) D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clinical nutrition 2012; 31(4):476-80.
  11. Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. European Journal of Endocrinology 2011; 164(5):741-9.
  12. Kim JJ, Choi YM, Chae SJ, Hwang KR, Yoon SH, Kim MJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clinical and experimental reproductive medicine 2014; 41(2):80.
  13. El-Shal AS, Shalaby SM, Aly NM, Rashad NM, Abdelaziz AM. Genetic variation in the vitamin D receptor gene and vitamin D serum levels in Egyptian women with polycystic ovary syndrome. Molecular biology reports 2013; 40:6063-73.
  14. Kozakowski J, Kapuścińska R, Zgliczyński W. Associations of vitamin D concentration with metabolic and hormonal indices in women with polycystic ovary syndrome presenting abdominal and gynoidal type of obesity. Ginekologia polska 2014; 85(10):765-70..
  15. Tsakova AD, Gateva AT, Kamenov ZA. 25 (OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res 2012; 82(6):399-404.
  16. Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, et al. Low levels of 25 (OH) D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clinical nutrition 2012; 31(4):476-80.
  17. Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clinical endocrinology 2012; 77(3):343-50.
  18. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011; 60(10):1475-81.
  19. Mahmoudi T. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertility and sterility 2009; 92(4):1381-3.
  20. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertility and Sterility 2010; 93(4):1208-14.
  21. Balen AH, Conway GS, Kaltsas G, Techatraisak K, Manning PJ, West C, et al. Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human reproduction 1995; 10(8):2107-11.
  22. Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. Journal of endocrinological investigation 2010; 33:234-8.
  23. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. American journal of obstetrics and gynecology 2010; 203(3):201-e1.
  24. Bonakdaran S, Mazloom Khorasani Z, Davachi B, Shakeri MT. Comparison of calcitriol and metformin effects on clinical and metabolic consequences of polycystic ovary syndrome. The Iranian Journal of Obstetrics, Gynecology and Infertility 2012; 14(8):16-24.
  25. Racowsky C. The releasing action of calcium upon cyclic AMP‐dependent meiotic arrest in hamster oocytes. Journal of Experimental Zoology 1986; 239(2):263-75.
  26. Mazloum Khorasani Z, Bonakdaran S. Relation between vitamin D deficiency and metabolic disturbance in PCOS. medical journal of mashhad university of medical sciences 2015; 58(1):1-6.
  27. Jamilian M, Bakhshayeshy S. To study the effect of calcium plus vitamin D supplementation on nitric oxide and biomarkers of oxidative stress in overweight and obess women with polycystic ovary syndrome. Arak Med Univ J (AMUJ) 2016; 19(6):27-36.
  28. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. European Journal of Endocrinology 2009; 161(4):575-82.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 26, Issue 10
December 2023
Pages 23-33

Files

Share

How to cite

Statistics